Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: RE: What do you make of this statement (Reply)

RE: What do you make of this statement (Reply)

posted on Jun 28, 2006 07:52AM
Hi All.

I might be wrong (and I usually am if you ask my long-suffering wife), but the statement about ``royalty rates are increasing according to plan`` has a dual thrust, though the first part is not exactly as most might think (or hope).

First, I believe at the SHM (I was not there, so someone who was jump in) Lecrone said collecting ongoing royalties was not in the cards and something they were not pursuing. My understanding is that the one-time licensing fee IS the ``royalty`` for having used the MMP IP.

Frankly, I like the latter part of the quoted sentence from the PR: ``increasing according to plan.`` That implies to me that PENTAX paid more than others that have come before it, because Lecrone made it clear that early berth licensees get a discount, but the rates will increase over time. Looks like that time may have arrived. I sure hope so.

Remember my ``pony metaphor`` from the other day? Now I see two hooves and part of a leg sticking out of that pile. I think its a quarterhorse (pun intended).

Cheers,

tps

Share
New Message
Please login to post a reply